Novavax states COVID vaccine initiates an immune response to the Omicron variant.
According to preliminary data released Wednesday, Novavax Inc’s COVID-19 vaccine initiative 2 an immune reaction against the Omicron variant, implying that the drugmaker’s established COVID-19 vaccine can help fight the innovative Omicron modified version.
The European Union and the World Health Organization approved Novavax’s 2 protein-based vaccines to be used this week. L1N2T50VX has previously been authorized in Indonesia and the Philippines but not in the United States.
Novavax received an extra higher dose of Novavax’s vaccine, which raised people’s immune reaction to Omicron. The information came from Novavax’s continued research into the vaccine’s efficacy in teenagers and as a booster.
“We are urged that boosted reactions against any variations in our Phase iii clinical trials were similar to those related to high vaccinated people,” stated “Gregory M. Glenn, head of state of research and innovation at Novavax.
Other COVID-related Preliminary data from 19 drugs companies, including Pfizer Inc. and Moderna Inc., show that Omicron increases immune function. People who received a supplemental booster dose have greater resistance in all cases.
Novavax was working on an Omicron-specific vaccine who said on Wednesday that it anticipates starting producing injections of the variant-specific shot in January.
As part of an agreement to supply up to 200 million dosages, the drugmaker will begin shipping immunizations to the EU’s 27 member states in January.
The business will also start shipments to COVAX, a WHO-managed vaccine allocation mechanism that distributes COVID-19 shots to poorer nations, in early 2022. Novavax and its companion, Serum Institute of India, have offered to send over 1.1 billion dosages of Novavax’s vaccine to COVAX.
Please stay connected with us for more info and news!